Assistant Attending Memorial Sloan Kettering Cancer Center New York, New York, United States
Recent data and professional guidelines are driving a need for patients get on the most appropriate targeted therapy or trial as quickly as possible. This need can be challenged, however, by the time, resources and costs required to perform and analyze CGP testing. In this workshop we review the development, validation and clinical implementation of Pillar Biosciences' rapid 21-gene solid tumor & heme panel oncoReveal Nexus by Memorial Sloan Kettering Cancer Center (MSKCC). We will review this assay's concordance with the MSKCC's MSK-IMPACT® panels and discuss how this type of rapid testing can be leveraged by other clinical laboratories as tool to help sub-select and inform which patients should have CGP testing performed.
